An important anti Cancer mechanism of CD279(PD-1) blockade elucidated
October 30, 2017
Often over time, an anti-Cancer immune response narrows into a few dominant (high affinity) CD8+ T cell clones. This Canadian Research group showed that blockading CD279 (PD-1) restored function of a wider array of sub dominant (lower affinity) anti-Cancer CD8+ T cell clones in a mouse in vivo model.
Related Ancell Research Products